Valuation: Rigel Pharmaceuticals, Inc.

Market Cap 681M 599M 557M 512M 960M 65.97B 977M 6.66B 2.6B 32.18B 2.56B 2.5B 112B P/E 2026 *
10.4x
P/E 2027 * 10.6x
Enterprise Value 681M 599M 557M 512M 960M 65.97B 977M 6.66B 2.6B 32.18B 2.56B 2.5B 112B EV / Sales 2026 *
2.46x
EV / Sales 2027 * 2.06x
Free-Float
96.61%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Rigel Pharmaceuticals, Inc.

1 day-0.94%
1 week-9.03%
Current month-5.73%
1 month+0.90%
3 months+21.76%
6 months-0.32%
Current year-13.89%
1 week 35.01
Extreme 35.0057
40.64
1 month 35.01
Extreme 35.0057
43.99
Current year 24.95
Extreme 24.95
49.1
1 year 19.51
Extreme 19.51
52.24
3 years 7.12
Extreme 7.12
52.24
5 years 6.4
Extreme 6.4
52.24
10 years 6.4
Extreme 6.4
55
Manager TitleAgeSince
Chief Executive Officer 65 2014-11-20
Director of Finance/CFO 63 2018-05-28
Compliance Officer 58 2022-11-30
Director TitleAgeSince
Director/Board Member 71 1997-02-28
Director/Board Member 65 2014-11-20
Chairman 67 2022-04-30
Date Insider Type Main position Quantity % Market Cap.
7/8/26 Free

Chief Technology Officer

24,400 0.1319%
6/22/26 Sell

Director

-2,500 0.0135%
6/17/26 Free

Compliance Officer

7,394 0.0400%
Change 5-day change 1-year change 3-year change Capi.($)
-0.94%-9.03%+80.52%+190.39% 681M
+1.30%+1.85%+49.10%+161.46% 1,057B
+1.27%+4.03%+55.24%+53.86% 624B
+0.69%+1.97%+35.98%+81.24% 454B
+1.60%+6.25%+33.95%+29.84% 341B
-0.60%+1.52%+35.68%+39.76% 297B
-0.14%+0.60%+16.17%+17.53% 262B
+0.09%-2.82%-28.29%-41.71% 215B
+1.25%+2.87%+22.13%+60.06% 201B
-0.89%-2.98%+15.09%+67.76% 162B
Average +0.42%-0.47%+31.56%+66.02% 361.46B
Weighted average by Cap. +0.86%+1.56%+35.96%+78.02%

Financials

2026 *2027 *
Net sales 277M 243M 226M 208M 390M 26.79B 397M 2.7B 1.05B 13.07B 1.04B 1.02B 45.33B 331M 291M 270M 249M 466M 32.05B 475M 3.23B 1.26B 15.63B 1.24B 1.22B 54.23B
Net income 70.19M 61.74M 57.35M 52.75M 98.92M 6.8B 101M 686M 268M 3.32B 264M 258M 11.5B 79.07M 69.54M 64.6M 59.42M 111M 7.66B 113M 773M 301M 3.73B 297M 290M 12.96B
Net Debt - -
Logo Rigel Pharmaceuticals, Inc.
Rigel Pharmaceuticals, Inc. is a biotechnology company. The Company is engaged in developing and providing therapies for patients with hematologic disorders and cancer. It focuses on products that address signaling pathways that are critical to disease mechanisms. Its products include TAVALISSE, REZLIDHIA, and GAVRETO. TAVALISSE is an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. REZLIDHIA is used for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation. GAVRETO is a once daily, small molecule, oral, kinase inhibitor of wild type rearranged during transfection (RET) and oncogenic RET fusions. It is used for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory.
Employees
173
Date Price Change Volume
26-07-24 US$36.89 +0.19% 174,920
26-07-23 US$36.82 -2.59% 383,198
26-07-22 US$37.80 -3.84% 331,743
26-07-21 US$39.31 -0.91% 456,768
26-07-20 US$39.67 -2.15% 363,057
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
36.82USD
Average target price
54.20USD
Spread / Average Target
+47.20%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. RIGL Stock